New analysis shows Cosentyx offers potential for disease modification

Swiss pharmaceutical company Novartis (NOVN: VX) has presented a series of papers detailing a new analysis of Cosentyx (secukinumab), which shows the drug may offer long-term disease modification in moderate-to-severe psoriasis.

The company says that Cosentyx is the first and only IL-17A inhibitor to “potentially modify the course of psoriasis.” The analysis shows that disease modification could be achieved for around 20% of patients following one year of treatment.

Following one year of treatment with Cosentyx, patients were randomized to either continuous treatment or treatment cessation until relapse.